The outlook for equity markets looks "decent" going into 2025, according to Barclays, as central banks cut interest rates and the global economy remains resilient. "Given limited valuation uplift for frothy parts of the market, global equities may struggle to deliver outsized risk-adjusted returns again in 2025. But they still screen favorably vs. bonds, cash and credit," the investment bank's analysts wrote in a Nov. 18 research note.
"We think now is a compelling entry point in AstraZeneca, as 2025 looks set to be a year of ground- breaking catalysts," the analysts explained. These catalysts include an $80-billion revenue target for 2030 which the company announced in May — around $10 billion higher than expected at the time. Shares in AstraZeneca are listed on the London and Stockholm Stock Exchanges and trade as an ADR in the U.S. under the ticker AZN .
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
European stocks could rally after US election into 2025, Barclays saysEuropean stocks could rally after US election into 2025, Barclays says
Consulte Mais informação »
Three Predictions For The 2025 Cloud MarketForrester is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth.
Consulte Mais informação »